We observed a statistically significant downregulation of FOXM1 in MSC from de novo AML and MDS, and therapy-related MN (t-MN), compared to HD (p = 0.0079, p < 0.0001, p = 0.0006 respectively, Fig. 2A). This evidence concerns the gene FOXM1 and myelodysplastic syndrome.